Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2015

View Archived Issues

Pfizer synthesizes new Abeta production inhibitors

Selective Nav1.7 inhibitors for the treatment of pain

IncellDx and Claremont to combine technologies for liquid-based biopsy system

JCR Pharma initiates development of ERT using BBB-crossing technology

Nanosyn and LLS update progress of MLL leukemia project

Piramal Enterprises presents BRD4 inhibitors

Sunshine Lake Pharma presents SGLT2 inhibitors

GDF15 may be a superior biomarker for mitochondrial disease diagnosis

Johnson & Johnson recaps highlights of first quarter 2015

Ombitasvir/paritaprevir/ritonavir HCV combination granted priority review in Japan

Avelas starts phase I trial of real-time fluorescent illuminator for breast cancer surgery

Baxter files for approval of BAX-855 in Japan

Isarna Therapeutics initiates first-in-human trial of ISTH-0036

Receptos's ozanimod achieves efficacy endpoints in phase II ulcerative colitis trial

TC-6499 fails to reduce gastric emptying time in diabetic gastroparesis study

Tipelukast receives FDA fast track designation for NASH with fibrosis

Actelion updates on clinical development of S1P1 receptor modulators

Discovery Laboratories advances development of Aerosurf, ceases commercialization of Surfaxin

World Hemophilia Day: Hyperfunctional FIX as a promising tool in hemophilia

Anacor reports boron-containing PDE4 inhibitors

Merck & Co. develops Trk-A inhibitors

FDA grants orphan drug designation to selumetinib for uveal melanoma

Chugai presents anti-protein-C MAbs

Provectus initiates phase III trial of PV-10 in melanoma

Genmab achieves fifth milestone in daratumumab collaboration with Janssen Biotech

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...